David Ross
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
David Ross has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
David Siegel
Department of Pharmaceutical Sciences, University of Colorado Denver, School of Pharmacy and Cancer Center, Denver, Colorado 80262
8 shared publicationsAdil Anwar
Department of Pharmaceutical Sciences, School of Pharmacy and Cancer Center, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
2 shared publicationsJadwiga K Kepa
Department of Pharmaceutical Sciences, Molecular Toxicology and Environmental Health Sciences Program, School of Pharmacy and Cancer Center, University of Colorado Health Sciences Center, Denver, CO 80262, USA
2 shared publicationsJulie L. Moran
Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, 4200 East, 9th Avenue, Denver, CO 80262, USA
2 shared publicationsAurélie Chilloux
School of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom, and Department of Pharmaceutical Sciences and Cancer Center, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, Colorado 80262
1 shared publicationBabette B. Weksler
Division of Hematology-Oncology, Weill Medical College, 1300 York Ave., NY 10021, USA
1 shared publication
Latest Publications
- 1 December 2008
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 97 (12) , 5147-5157
Stability of the Hsp90 Inhibitor 17AAG Hydroquinone and Prevention of Metal‐Catalyzed Oxidation
- 1 December 2008
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 97 (12) , 5147-5157
Stability of the Hsp90 Inhibitor 17AAG Hydroquinone and Prevention of Metal‐Catalyzed Oxidation
- 29 August 2008
- Published by Springer Nature
- p. 1-29
One- and Two-Electron-Mediated Reduction of Quinones: Enzymology and Toxicological Implications
- 29 August 2008
- Published by Springer Nature
- p. 1-29
One- and Two-Electron-Mediated Reduction of Quinones: Enzymology and Toxicological Implications
- 18 October 2007
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (23) , 5780-5789
Synthesis and Evaluation of 3-Aryloxymethyl-1,2-dimethylindole-4,7-diones as Mechanism-Based Inhibitors of NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Activity
NAD(P)H:quinone oxidoreductase 1 is a proposed target in pancreatic cancer. We describe the synthesis of a series of indolequinones, based on the 5- and 6-methoxy-1,2-dimethylindole-4,7-dione chromophores with a range of phenolic leaving groups at the (indol-3-yl)methyl position. The ability of these indolequinones to function as mechanism-based inhibitors of purified recombinant human NQO1 was evaluated, as was their ability to inhibit both NQO1 and cell growth in human pancreatic MIA PaCa-2 tumor cells. The inhibition of rhNQO1 was related to the pKa of the leaving group: compounds with poorer phenolic leaving groups were poor inhibitors whereas those with more acidic leaving groups were more efficient inhibitors. These inhibition data also correlated with the inhibition NQO1 in MIA PaCa-2 cells. However, the data demonstrate that NQO1 inhibition does not correlate with growth inhibitory activity, at least in the MIA PaCa-2 cell line, suggesting that targets in addition to NQO1 need to be considered to explain the potent growth inhibitory activity of this series of indolequinones in human pancreatic cancer cells.
- 18 October 2007
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (23) , 5780-5789
Synthesis and Evaluation of 3-Aryloxymethyl-1,2-dimethylindole-4,7-diones as Mechanism-Based Inhibitors of NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Activity
NAD(P)H:quinone oxidoreductase 1 is a proposed target in pancreatic cancer. We describe the synthesis of a series of indolequinones, based on the 5- and 6-methoxy-1,2-dimethylindole-4,7-dione chromophores with a range of phenolic leaving groups at the (indol-3-yl)methyl position. The ability of these indolequinones to function as mechanism-based inhibitors of purified recombinant human NQO1 was evaluated, as was their ability to inhibit both NQO1 and cell growth in human pancreatic MIA PaCa-2 tumor cells. The inhibition of rhNQO1 was related to the pKa of the leaving group: compounds with poorer phenolic leaving groups were poor inhibitors whereas those with more acidic leaving groups were more efficient inhibitors. These inhibition data also correlated with the inhibition NQO1 in MIA PaCa-2 cells. However, the data demonstrate that NQO1 inhibition does not correlate with growth inhibitory activity, at least in the MIA PaCa-2 cell line, suggesting that targets in addition to NQO1 need to be considered to explain the potent growth inhibitory activity of this series of indolequinones in human pancreatic cancer cells.
- 13 April 2007
- Published by Wiley in Journal of Neurochemistry
- Vol. 102 (3) , 913-921
A comparative study of proteasomal inhibition and apoptosis induced in N27 mesencephalic cells by dopamine and MG132
Dopamine (DA) and its metabolites have been implicated in the pathogenesis of Parkinson’s disease. DA can produce reactive‐oxygen species and DA‐derived quinones such as aminochrome can induce proteasomal inhibition. We therefore examined the ability of DA and MG132 to induce apoptosis and proteasomal inhibition in N27 rat dopaminergic cells. DA (0–500 μmol/L, 0–24 h) and MG132 (0–5 μmol/L, 0–24 h) treated N27 cells resulted in time‐ and concentration‐dependent apoptosis. To better define DA and MG132‐induced apoptosis, the activation of initiator caspases 2 and caspase 9 and the executioner caspase 3 was investigated. Activation of caspase 2, caspase 9, and caspase 3 occurred early and prior to cell death. In addition, N‐acetylcysteine (NAC) blocked DA but not MG132‐induced apoptosis and mitochondrial membrane potential loss. NAC can react with both reactive‐oxygen and quinoid metabolites and its inhibitory activity suggests a role for reactive species in DA‐induced apoptosis. Proteasomal inhibition was detected after DA treatment in N27 cells which occurred prior to cell death and was abrogated by NAC. Our results implicate DA‐derived reactive species in proteasomal inhibition and caspase‐dependent apoptosis in N27 cells. The ability of endogenous DA‐derived metabolites to induce proteasomal inhibition and apoptosis may contribute to the selective loss of dopaminergic neurons in Parkinson’s disease.
- 13 April 2007
- Published by Wiley in Journal of Neurochemistry
- Vol. 102 (3) , 913-921
A comparative study of proteasomal inhibition and apoptosis induced in N27 mesencephalic cells by dopamine and MG132
Dopamine (DA) and its metabolites have been implicated in the pathogenesis of Parkinson’s disease. DA can produce reactive‐oxygen species and DA‐derived quinones such as aminochrome can induce proteasomal inhibition. We therefore examined the ability of DA and MG132 to induce apoptosis and proteasomal inhibition in N27 rat dopaminergic cells. DA (0–500 μmol/L, 0–24 h) and MG132 (0–5 μmol/L, 0–24 h) treated N27 cells resulted in time‐ and concentration‐dependent apoptosis. To better define DA and MG132‐induced apoptosis, the activation of initiator caspases 2 and caspase 9 and the executioner caspase 3 was investigated. Activation of caspase 2, caspase 9, and caspase 3 occurred early and prior to cell death. In addition, N‐acetylcysteine (NAC) blocked DA but not MG132‐induced apoptosis and mitochondrial membrane potential loss. NAC can react with both reactive‐oxygen and quinoid metabolites and its inhibitory activity suggests a role for reactive species in DA‐induced apoptosis. Proteasomal inhibition was detected after DA treatment in N27 cells which occurred prior to cell death and was abrogated by NAC. Our results implicate DA‐derived reactive species in proteasomal inhibition and caspase‐dependent apoptosis in N27 cells. The ability of endogenous DA‐derived metabolites to induce proteasomal inhibition and apoptosis may contribute to the selective loss of dopaminergic neurons in Parkinson’s disease.
- 1 May 2005
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 153-154, 137-146
Functions and distribution of NQO1 in human bone marrow: Potential clues to benzene toxicity
- 1 May 2005
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 153-154, 137-146
Functions and distribution of NQO1 in human bone marrow: Potential clues to benzene toxicity
- 20 October 2004
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 149 (2-3) , 177-188
Stimulation of endothelial IL-8 (eIL-8) production and apoptosis by phenolic metabolites of benzene in HL-60 cells and human bone marrow endothelial cells
- 20 October 2004
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 149 (2-3) , 177-188
Stimulation of endothelial IL-8 (eIL-8) production and apoptosis by phenolic metabolites of benzene in HL-60 cells and human bone marrow endothelial cells
- 1 May 2004
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (9) , 3147-3155
Development of a New Isogenic Cell-Xenograft System for Evaluation of NAD(P)H:Quinone Oxidoreductase-Directed Antitumor Quinones
Purpose: The purpose of our study was to develop and validate an isogenic cell line pair that differs only in the expression of NAD(P)H:quinone oxidoreductase (NQO1) that can be used to examine the in vitro and in vivo role of NQO1 in the bioactivation of the antitumor quinone RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), a compound currently in Phase I clinical trials. Experimental Design: MDA-MB-468 (MDA468) human breast adenocarcinoma cells, homozygous for a polymorphism in NQO1 (NQO1*2/*2) and with low levels of NQO1 activity, were stably transfected with human NQO1 to generate a clone (NQ16) expressing very high NQO1 activity. We examined levels of other reductases and looked at biochemical systems that might influence response to antitumor quinones to validate that the isogenic cell line pair differed only in the expression of NQO1. The 3-(4,5-dimethylthiazol-2,5-diphenyl)tetrazolium (MTT) assay was used to determine the differential toxicity of various quinones, including the most recent NQO1-directed antitumor quinone, RH1, between the two cell lines. Human tumor xenografts were established from both MDA468 and NQ16 cells, and the antitumor activity of RH1 was evaluated. Results: Levels of cytochrome P450 reductase, cytochrome b5 reductase, soluble thiols, and superoxide dismutase in the NQ16 line were unchanged from the parental line. The functional significance of wild-type NQO1 expression was confirmed by measurement of the differential toxicity of compounds activated or deactivated by NQO1 in the two cell lines. The toxicity of the NQO1-directed antitumor quinones RH1 and streptonigrin were markedly greater and the toxicity of menadione, which is detoxified by NQO1, was ameliorated in the NQ16 line. High levels of NQO1 expression were observed throughout xenograft tumors established from the NQ16 cell line. RH1 treatment was effective at statistically reducing tumor volume in NQ16 xenografts at all of the doses tested [0.1, 0.2, 0.4 mg/kg every day for 5 days), whereas only the highest dose of RH1 resulted in a significant reduction in tumor volume in MDA468 xenografts. Conclusions: The MDA468/NQ16 isogenic cell line pair is a useful model system for evaluating the role of NQO1 in the bioactivation of antitumor quinones in both cell lines and xenografts. In addition, our data demonstrate that the novel antitumor quinone RH1, is effectively activated by NQO1 both in vitro and in vivo.
- 1 May 2004
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (9) , 3147-3155
Development of a New Isogenic Cell-Xenograft System for Evaluation of NAD(P)H:Quinone Oxidoreductase-Directed Antitumor Quinones
Purpose: The purpose of our study was to develop and validate an isogenic cell line pair that differs only in the expression of NAD(P)H:quinone oxidoreductase (NQO1) that can be used to examine the in vitro and in vivo role of NQO1 in the bioactivation of the antitumor quinone RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), a compound currently in Phase I clinical trials. Experimental Design: MDA-MB-468 (MDA468) human breast adenocarcinoma cells, homozygous for a polymorphism in NQO1 (NQO1*2/*2) and with low levels of NQO1 activity, were stably transfected with human NQO1 to generate a clone (NQ16) expressing very high NQO1 activity. We examined levels of other reductases and looked at biochemical systems that might influence response to antitumor quinones to validate that the isogenic cell line pair differed only in the expression of NQO1. The 3-(4,5-dimethylthiazol-2,5-diphenyl)tetrazolium (MTT) assay was used to determine the differential toxicity of various quinones, including the most recent NQO1-directed antitumor quinone, RH1, between the two cell lines. Human tumor xenografts were established from both MDA468 and NQ16 cells, and the antitumor activity of RH1 was evaluated. Results: Levels of cytochrome P450 reductase, cytochrome b5 reductase, soluble thiols, and superoxide dismutase in the NQ16 line were unchanged from the parental line. The functional significance of wild-type NQO1 expression was confirmed by measurement of the differential toxicity of compounds activated or deactivated by NQO1 in the two cell lines. The toxicity of the NQO1-directed antitumor quinones RH1 and streptonigrin were markedly greater and the toxicity of menadione, which is detoxified by NQO1, was ameliorated in the NQ16 line. High levels of NQO1 expression were observed throughout xenograft tumors established from the NQ16 cell line. RH1 treatment was effective at statistically reducing tumor volume in NQ16 xenografts at all of the doses tested [0.1, 0.2, 0.4 mg/kg every day for 5 days), whereas only the highest dose of RH1 resulted in a significant reduction in tumor volume in MDA468 xenografts. Conclusions: The MDA468/NQ16 isogenic cell line pair is a useful model system for evaluating the role of NQO1 in the bioactivation of antitumor quinones in both cell lines and xenografts. In addition, our data demonstrate that the novel antitumor quinone RH1, is effectively activated by NQO1 both in vitro and in vivo.
- 1 January 2004
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 36 (3-4) , 639-654
Quinone Reductases Multitasking in the Metabolic World
The multiple functions of NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) in the cell are reviewed. NQO1 has long been viewed as a chemoprotective enzyme involved in cellular defense against the electrophilic and oxidizing metabolites of xenobiotic quinones. It also participates in reduction of endogenous quinones, such as vitamin E quinone and ubiquinone, generating antioxidant forms of these molecules. NQO1 has recently been shown to interact with superoxide and may be involved in scavenging superoxide within the cell. In addition, the possible role of NQO1 in p53 stabilization and consequently in contributing to p53-dependent stress responses is summarized. Such protein multitasking is a good strategy in terms of cellular economy. NQO1 can also be exploited in the design of NQO1-directed antitumor agents such as the new aziridinylbenzoquinone RH1 and Hsp90 inhibitors such as 17AAG. Polymorphisms in NQO1 which have profound influence on phenotype such as the NQO1*2 polymorphism may influence the chemoprotective actions of NQO1, and should be considered when NQO1-directed antitumor quinones are used for therapy in patients.
- 1 January 2004
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 36 (3-4) , 639-654
Quinone Reductases Multitasking in the Metabolic World
The multiple functions of NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) in the cell are reviewed. NQO1 has long been viewed as a chemoprotective enzyme involved in cellular defense against the electrophilic and oxidizing metabolites of xenobiotic quinones. It also participates in reduction of endogenous quinones, such as vitamin E quinone and ubiquinone, generating antioxidant forms of these molecules. NQO1 has recently been shown to interact with superoxide and may be involved in scavenging superoxide within the cell. In addition, the possible role of NQO1 in p53 stabilization and consequently in contributing to p53-dependent stress responses is summarized. Such protein multitasking is a good strategy in terms of cellular economy. NQO1 can also be exploited in the design of NQO1-directed antitumor agents such as the new aziridinylbenzoquinone RH1 and Hsp90 inhibitors such as 17AAG. Polymorphisms in NQO1 which have profound influence on phenotype such as the NQO1*2 polymorphism may influence the chemoprotective actions of NQO1, and should be considered when NQO1-directed antitumor quinones are used for therapy in patients.
- Open Access
- 1 April 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (16) , 14060-14067
Interaction of the Molecular Chaperone Hsp70 with Human NAD(P)H:Quinone Oxidoreductase 1
- 1 April 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (16) , 14060-14067
Open AccessInteraction of the Molecular Chaperone Hsp70 with Human NAD(P)H:Quinone Oxidoreductase 1